BHCM
ABEO icon

Brevan Howard Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Brevan Howard Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$131K Buy
29,263
+7,556
+35% +$37.8K ﹤0.01% 1981
2025
Q4 		$114K Buy
+21,707
New +$109K ﹤0.01% 1666

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Brevan Howard Capital Management's ABEO Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Abeona Therapeutics (ABEO) stake by 35% in Q1 2026, buying an estimated $37.8K and bringing the position to 29,263 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #1981.

Brevan Howard Capital Management first reported a position in ABEO in Q4 2025 and has held it in 2 quarters since. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Brevan Howard Capital Management held 29,263 shares of Abeona Therapeutics worth $131K as of Q1 2026.
  • Brevan Howard Capital Management bought 7,556 Abeona Therapeutics shares in Q1 2026, an estimated $37.8K.
  • Abeona Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1981 holding.
  • Brevan Howard Capital Management first reported a position in Abeona Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.